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Background: Colony stimulating factor-1 (CSF-1) plays an important role in ovarian cancer biology and as a
prognostic factor in ovarian cancer. Elevated levels of CSF-1 promote progression of ovarian cancer, by binding to
CSF-1R (the tyrosine kinase receptor encoded by c-fms proto-oncogene).
Post-transcriptional regulation of CSF-1 mRNA by its 3’ untranslated region (3’UTR) has been studied previously.
Several cis-acting elements in 3’UTR are involved in post-transcriptional regulation of CSF-1 mRNA. These include
conserved protein-binding motifs as well as miRNA targets. miRNAs are 21-23nt single strand RNA which bind the
complementary sequences in mRNAs, suppressing translation and enhancing mRNA degradation.
Results: In this report, we investigate the effect of miRNAs on post-transcriptional regulation of CSF-1 mRNA in
human ovarian cancer. Bioinformatics analysis predicts at least 14 miRNAs targeting CSF-1 mRNA 3’UTR. By
mutations in putative miRNA targets in CSF-1 mRNA 3’UTR, we identified a common target for both miR-128 and
miR-152. We have also found that both miR-128 and miR-152 down-regulate CSF-1 mRNA and protein expression
in ovarian cancer cells leading to decreased cell motility and adhesion in vitro, two major aspects of the metastatic
potential of cancer cells.
Conclusion: The major CSF-1 mRNA 3’UTR contains a common miRNA target which is involved in post-
transcriptional regulation of CSF-1. Our results provide the evidence for a mechanism by which miR-128 and miR-
152 down-regulate CSF-1, an important regulator of ovarian cancer.
Keywords: miR-128, miR-152, CSF-1 mRNA, Post-transcriptional regulation, motility and adhesionBackground
The colony stimulating factor-1 (CSF-1) and its receptor
CSF-1R (encoded by the c-fms proto-oncogene) com-
prise a reciprocal system that has been previously linked
to several human epithelial cancers including ovarian,
breast, and prostate cancers [1-4]. Besides its critical role
in macrophage differentiation and proliferation [5], CSF-
1 and c-fms are also key players in bone metabolism [6]
and female reproduction [7]. In ovarian cancer, CSF-1
also has an important role as a biomarker and prognos-
tic factor, as high levels of this protein were linked to
poor patient outcome [8,9]. CSF-1 was also associated
with cancer virulence by having the capacity to augment* Correspondence: hwoo@azcc.arizona.edu; schambers@azcc.arizona.edu
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reproduction in any medium, provided the orthe invasive ability of human ovarian cancer cells [10],
and by promoting metastasis [11].
CSF-1 has several alternatively spliced transcripts that
encode for different sizes of CSF-1 proteins with differ-
ent functionality [12]. Its biological function as a cyto-
kine in autocrine and paracrine signaling is achieved
mostly by a secreted form that is the product of a
3,939nt transcript excluding poly A+ tail [13]. This tran-
script contains a long, 2,172nt 3’UTR. In ovarian cancer
cells, a major unprocessed CSF-1 of 60.1 kDa polypep-
tide is produced by the 3,939nt transcript. This mono-
mer is processed further by glycosylation and forms an
over 200 kDa homodimeric glycoprotein which is the
most abundant form of secreted CSF-1 in ovarian cancer
[14,15].
Among the CSF-1 regulatory events, major importance
is attributed to CSF-1 post-transcriptional regulationd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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we identified GAPDH protein which binds to ARE and
stabilizes CSF-1 mRNA leading to post-transcriptional
up-regulation of CSF-1 in ovarian cancer cells [16].
MicroRNAs (miRNAs) are small single-strand RNAs
of 21–23 nucleotides in length that regulate several
biological functions (i.e., differentiation, hematopoiesis,
tumorigenesis, apoptosis, development, and cell pro-
liferation) through modulating the stability and/or
translation efficiency of target mRNAs [17]. They are
predicted to regulate about 60% of mammalian mRNAs
[18]. It has been found that mRNAs with long 3’UTRs
are more susceptible to miRNA regulation than those
with short 3’UTRs as the latter ones lack in number of
binding sites necessary for multiple miRNA binding and
regulation [19].
Although previous studies have reported miRNA regu-
lation of CSF-1, most of these describe indirect regula-
tion through additional miRNA targeted proteins in
non-ovarian cells [20]. To the best of our knowledge,
there are only two previous reports of a miRNA that
shows direct CSF-1 regulatory abilities in an ovarian
system [21,22].
We predict that, since the 3,939nt CSF-1 transcript
has a vast (2,172nt) 3’UTR, miRNAs may play an im-
portant regulatory role in mediating the cellular levels
and biological functions of CSF-1 in ovarian cancer. In
this report, we study 3’UTR targets for binding miR-
NAs, and find that both miR-128 and miR-152 down-
regulate CSF-1 expression in ovarian cancer. Our goal is
to identify miRNAs that down-regulate CSF-1 expres-
sion, and eventually open an avenue for possible treat-
ment options for ovarian carcinomas.
Results
Bioinformatics analysis of potential miRNAs targeting
CSF-1 mRNA 3’UTR
To assess the most common miRNA target sequences
located in the 3’UTR of the 3,939nt CSF-1 mRNA, we
used the MirWalk text-mining algorithm [23] applied to
the mirBase-15 database [24]. This search engine uses
its own algorithm to find putative miRNA binding sites
for a gene of interest and also compares its findings with
a number of other search tools (i.e., miRanda, miRDB,
miRWalk, PicTar, PITA, RNA22 and TargetScan/Tar-
getScanS (version 5.1) [18,23,25-31]. This search reveals
the putative target sequence ‘2573CACUG2577’ which has
the most hits with 14 miRNAs having at least a hit num-
ber of 4 (miR-27a/b, -128, -130a/b, -135a/b, -148a/b,
-152, -214, -301a/b, -454) (Table 1). Among these miR-
NAs, we focused on 7 miRNAs, or 50%, of these miR-
NAs. Selected miRNAs for further analysis in this
report are miR-152, -128, -27a, -214, -454; with results
concerning the role of miR-130a and miR-301a inanother context to be reported elsewhere (Woo et al.
unpublished).
Expression of miR-128, miR-152, miR-27a, miR-214, and
miR-454 in ovarian cancer cells
To correlate selected miRNA expression patterns with
CSF-1 mRNA and protein expression, we used three
ovarian cancer cell lines and NOSE.1 ovarian epithelial
cells which are minimally invasive [32]. Bix3 ovarian
cancer cells are less invasive compared to the metastatic
and more invasive ovarian cancer cells, Hey and SKOV3
[10]. Bix3 also express a low level of CSF-1 compared to
Hey and SKOV3, which express high levels of CSF-1
mRNA and also secreted CSF-1 protein (Figure 1A, B).
In addition, NOSE.1 express intermediate amounts of
CSF-1 mRNA and secreted CSF-1 protein, and was used
for comparison of miRNA expression. Expression of
miR-128 is significantly inversely correlated with CSF-1
protein expression (correlation coefficient =−0.998,
p = 0.002), with miR-128 RNA level low in Hey and
SKOV3 and high in Bix3 ovarian cancer cells, as well as
in NOSE.1 ovarian cells (Figure 1C). In contrast, expres-
sion of miR-152 appears to be positively correlated with
CSF-1 expression, with miR-152 expressed at a high
level in Hey and SKOV3 with lower expression seen in
Bix3 cells and minimal expression in NOSE.1 cells
(Figure 1D), but this correlation was not statistically sig-
nificant. The expression patterns of the remaining 3
miRNAs were more variable. miR-27a and miR-214 are
expressed highly in SKOV3 cells compared to other
cell lines (Figure 1E, F). miR-454 is expressed more in
SKOV3 and NOSE.1 cells than Hey and Bix3 cells
(Figure 1G). Their expression patterns were not signifi-
cantly correlated with CSF-1 mRNA or protein expres-
sion (P =NS).
Since generally miRNAs are known to down-regulate
target mRNAs, we would expect that CSF-1 mRNA and
miRNA levels would be inversely correlated. However,
there are also reports that some miRNAs are involved in
up-regulation of translation [33]. This usually occurs
through a feedback loop when the target mRNA is indir-
ectly regulated by upstream inducers or inhibitors. To
address this issue, we decided to study, in more detail,
the roles of miR-128 (as being inversely correlated to
CSF-1 expression) and miR-152 (as appearing to be most
positively correlated to CSF-1 expression) in the post-
transcriptional regulation of CSF-1 expression.
Expression pattern between host genes and miRNAs
correlate with each other
To further confirm the expression pattern of miR-128
and miR-152 in ovarian cancer cells, we applied the
Splinted Ligation technique to directly detect these
miRNAs [34]. miR-128 RNA is detected in both
Table 1 Summary of bioinformatics analysis of 14 miRNAs targeting CSF-1 mRNA 3’UTR, having hit numbers ≥4
miRANDA miRDB miRWalk PICTAR4 PITA RNA22 Targetscan Sum
miR-152 1 0 1 1 1 1 1 6
miR-128 1 1 1 0 1 0 1 5
miR-27a 1 0 1 1 1 1 0 5
miR-27b 1 0 1 1 1 1 0 5
miR-214 1 1 0 1 1 0 1 5
miR-130a 1 0 1 1 1 1 0 5
miR-130b 1 0 1 1 1 1 0 5
miR-301a 1 1 1 0 1 0 0 4
miR-301b 1 1 1 0 1 0 0 4
miR-454 1 0 1 1 1 0 0 4
miR-135a 1 0 1 1 1 0 0 4
miR-135b 1 0 1 1 1 0 0 4
miR-148a 1 0 1 1 1 0 0 4
miR-148b 1 0 1 1 1 0 0 4
1 = hit, 0 = no hit.
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SKOV3 ovarian cancer cells (Figure 2A). In contrast,
miR-152 RNA is detected in Hey and SKOV3 cells,
and not detectable in NOSE.1 and Bix3 cells
(Figure 2B). These results correlate well with qRT-PCR
data (Figure 1C, D).
Since profiling of host mRNA expression could be cor-
related to the expression pattern of microRNAs, the
knowledge of the relative expression pattern of miRNAs
and their “host” genes would allow for a better profiling
of the miRNA expression. This aspect could be import-
ant when using the expression of a certain miRNA as a
biomarker to correlate with disease outcome. miR-128 is
highly expressed in human brain tissue and its function
is linked to neuronal differentiation [35]. miR-128 gene
is imbedded in two paralogous genes, both present in
the intronic region of their respective “host” genes.
miR-128-1 is in R3HDM1 gene on chromosome 2q21.3
and miR-128-2 is in ARPP21 gene on chromosome
3p22. Both gene products are processed into the same
mature miR-128 [36]. miR-152 belongs to the miR-148
family whose putative role is still elusive, but it has been
studied in hepatic [37], cervical [38], and brain cancers
[39]. miR-152 gene is imbedded in the intronic region of
COPZ2 gene, which is a subunit of coatomer protein
complex 1 (COP1) known to be responsible for Golgi to
ER transport [40].
In both cases, expressions of miR-128 and miR-152
follow their host gene expression patterns (Figure 2C,
D). The slight discrepancies between host gene and
miRNA expression pattern may be due to differential
processing that is involved during the maturation of
mRNAs and miRNAs.CSF-1 mRNA 3’UTR is a direct target for miR-128 and miR-
152 in ovarian cancer cells
The miRanda v3.0 target scanning algorithm predicts
two target regions (Target-A and –C) for miR-128 and
two target regions (Target-A, and -B) for miR-152 in the
2,172nt CSF-1 mRNA 3’UTR (Figure 3A). All three tar-
gets share the common sequence of ‘CACUG’. These
two miRNAs are related through a Target-A sequence at
region 2573–2577. This Target-A sequence appears to
be important for CSF-1 regulation by miRNAs because
it is predicted to be a target sequence for several miR-
NAs. Moreover, the ‘CACUG’ comprising these target
sequences was described as a conserved target motif that
conferred miRNA regulation to its mRNA 3’UTR region
in mouse embryonic stem cells [41].
To find the actual target sequence for miR-128 and
miR-152, we used a luciferase reporter system. A full
length wild type 2,172nt CSF-1 mRNA 3’UTR was ligated
at the 3’-end of luciferase RNA. In addition, the three indi-
vidual target sequences within the wild type 3’UTR se-
quence were individually point-mutated from ‘CACUG’ to
‘CGCGC’ and ligated to the 3’-end of luciferase RNA
(Figure 3A). These constructs were transfected into Bix3
cells. Only the Target-A mutation (M2573 construct)
increased both luciferase RNA level by 8.38-fold
(p< 0.001) and luciferase activity by 2.43-fold (p< 0.001)
compared to wild type sequence (Figure 3B, C). There was
no significant difference (p=NS) between the effects of
Target-B mutation, Target-C mutation, or the wild type se-
quence. This data suggests that Target-A is a cis-acting
regulatory sequence in CSF-1 mRNA 3’UTR which may
respond to miRNAs. This data also suggests that both
miRNAs have more effects at the RNA than protein levels.
Figure 1 A) Expression of CSF-1 mRNA in ovarian cancer cells. B) Secreted CSF-1 protein levels detected by ELISA. C) miR-128 RNA level is
high in Bix3 ovarian cancer cells compared to Hey and SKOV3 ovarian cancer cells. D) miR-152 RNA level is low in less aggressive Bix3 cells
compared to Hey and SKOV3 cells. E) miR-27a RNA level in ovarian cancer cells. F) miR-214 RNA level in ovarian cancer cells. G) miR-454 RNA
level in ovarian cancer cells. Bars represent mean± SD of triplicate experiments.
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responding sequence, miR-128 or miR-152 was overex-
pressed together with either wild type construct (Luc-
CSF-1 3’UTR-Wt) or Target-A mutant construct (Luc-
CSF-1 3’UTR-Mut). Overexpression of either miR-128
or miR-152 in Bix3 cells co-transfected with the wild
type construct decreased luciferase RNA by 39% and
93%, respectively (p < 0.001). Luciferase activity was
decreased by 40% in response to miR-152 overexpres-
sion (p = 0.006) (Figure 4A,B). Overexpression of miR-
128 in these cells already overexpressing high levels of
endogenous miR-128 (Figure 1C), does not change luci-
ferase activity (p =NS). In this context, exogenously
introduced miR-128 may not have a strong influence on
luciferase translation. In contrast, overexpression of ei-
ther miR-128 or miR-152 in Bix3 cells transfected with
the Target-A mutant construct did not decreaseluciferase RNA significantly (p =NS) compared to the
wild type construct (Figure 4C). In the presence of the
Target-A mutant construct, miR-128 overexpression also
had no significant effect (p =NS) on luciferase activity.
There was a small but statistically significant (p = 0.03)
decrease in luciferase activity by miR-152 overexpression
(Figure 4D). Comparison of Figures 4B and 4D, however,
demonstrate that the Target-A mutation construct
largely attenuates the effect of miR-152 overexpression
on luciferase activity. This suggests that both miRNAs
target this region Target-A (2573CACUG2577) in CSF-1
mRNA 3’UTR.
miR-128 and miR-152 down-regulate CSF-1 mRNA and
protein expression
To determine the effects of miR-128 and miR-152 on
the expression of CSF-1, either miR-128 or miR-152
Figure 2 A) Splinted ligation of miR-128 in ovarian cancer cells. miR-128 RNA is detected in both NOSE.1 and Bix3 cells. B) Splinted ligation
of miR-152 in ovarian cancer cells. miR-152 RNA is detected in both Hey and SKOV3 cells. C) miRNA expression pattern follows “host” gene
expression pattern. R3HDM1 mRNA expression in ovarian cancer cells. D) COPZ2 mRNA expression in ovarian cancer cells. GAPDH mRNA was
used as a loading control in qRT-PCR. Bars represent mean± SD from triplicate experiments.
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ovarian cancer cells. In SKOV3, overexpression of miR-
128 decreased CSF-1 mRNA level by 92% (p < 0.001)
(Figure 5A) and CSF-1 protein levels (~60 kDa) by 87%
(Figure 5C). In SKOV3, overexpression of miR-152




































Figure 3 A) Luciferase reporter constructs with 2,172nt full length CS
Either CSF-1 mRNA 3’UTR wild type, Target-A point-mutation (M2573), Targ
sequences were cloned. B) Only Target-A construct results in an increase in
mean± SD from triplicate experiments.(Figure 5A) and CSF-1 protein levels (~60 kDa) by 73%
(Figure 5C). In contrast, in SKOV3, inhibition of miR-
128 increased CSF-1 mRNA level by 3.73-fold (p < 0.001)
(Figure 5B) and CSF-1 protein level by 13.61-fold
(Figure 5C). In SKOV3, inhibition of miR-152 increased



























F-1 mRNA 3’UTR cloned at the 3’-end of the luciferase mRNA.
et-B point-mutation (M2672), or Target-C point-mutation (M3797)
luciferase RNA and C) luciferase activity in Bix3 cells. Bars represent
Figure 4 Target-A is an active target for miR-128 and miR-152. Either miR-128 or miR-152 was overexpressed together with either A, B) wild
type construct (Luc-CSF-1 3’UTR-Wt) or C, D) Target-A mutant construct (Luc-CSF-1 3’UTR-Mut) in Bix3 cells. Bars represent mean± SD from
triplicate experiments.
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both miRNA levels showed more effect on CSF-1 pro-
tein levels than mRNA levels in SKOV3.
In Bix3 cells, the miRNA effect is less significant than in
SKOV3 cells. Overexpression of miR-128 does not alter
CSF-1 mRNA (p=NS) or protein levels (Figure 5D, F).
Since endogenous miR-128 RNA level is already high in
Bix3 (Figure 1C), overexpression by exogenously intro-
duced miR-128 RNA may have little effect on CSF-1 ex-
pression. In contrast, inhibition of miR-128 increased
CSF-1 mRNA level by 3.01-fold (p < 0.001) (Figure 5E)
and CSF-1 protein level (~60 kDa) by 2.45-fold
(Figure 5F). In Bix3, overexpression of miR-152 decreased
CSF-1 mRNA level by 61% (p< 0.001) (Figure 5D) and
protein levels by 64% (Figure 5F). In contrast, inhibition of
miR-152 increased CSF-1 mRNA level by 3.32-fold
(p < 0.001) (Figure 5E) and CSF-1 protein level (~60 kDa)
by 1.22-fold (Figure 5F). Either overexpression or inhib-
ition of miR-152 has effect on both CSF-1 mRNA and
protein levels.
While some differential effects of miRNA alteration
are seen between the different ovarian cancer cell lines,
overall, the effect of miR-128 and −152 on down-
regulation of CSF-1 expression are similar, and may be
achieved by both translational repression and mRNA
decay. This down-regulation of CSF-1 mRNA by bothmiRNAs is observed in the context of differing miRNA
expression patterns in the ovarian cancer cells.
miR-128 and miR-152 inhibit cellular motility and
adhesion of ovarian cancer cells
It has been previously established that CSF-1 imparts
invasiveness and metastasis in epithelial ovarian cancer
[8,10,11]. We have shown that this is due, at least in
part, to CSF-1 regulation of uPA, a well-known marker
of invasiveness in ovarian cancer [10]. It was also re-
cently revealed that both miR-128 and miR-152 have the
ability to inhibit neuroblastoma cell motility and inva-
siveness when overexpressed [39].
We studied the ability of Hey ovarian cancer cells to
either adhere to a human derived simple matrix-coated
plate in an adhesion assay or translocate through an
8 μm pore-size membrane towards chemo-attractants in
a motility assay. The motility of Hey cells was signifi-
cantly curtailed by over 50% by the overexpression of ei-
ther miR-128 or miR-152 (p < 0.001) (Figure 6A).
Furthermore, overexpression of miR-128 or miR-152
in Hey cells inhibited cell adhesiveness by 15-20%
(p < 0.001) (Figure 6B). At the same time, overexpression
of miR-128 had no significant effect on viability (p =NS)
(Figure 6C). There was a small effect by overexpression


































































































































Figure 5 miR-128 and miR-152 inhibit CSF-1 expression in SKOV3 and Bix3 cells. Either SKOV3 or Bix3 cells were transfected with the A, D)
miR-128 or miR-152 overexpression plasmids (miR-128OE, miR-152OE); or B, E) inhibitor plasmids (miR-128Inh, miR-152Inh); or vector controls.
C, F) CSF-1 protein (~60 kDa) levels in SKOV3 and Bix3 cells were detected by immunoblot analysis. mRNA and protein expression levels were
normalized by the levels of GAPDH mRNA and actin, respectively. Bars represent mean± SD from triplicate experiments.
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152 can negatively impact cell motility and adhesiveness
of human ovarian cancer cells, important aspects of their
metastatic potential, correlated with suppression of CSF-
1 expression.
Discussion
CSF-1 is an established regulator of ovarian cancer biol-
ogy [8-11], imparting invasiveness and metastasis [9,11],
making it a potentially appropriate therapeutic target.
The relatively long 3’UTR of CSF-1 mRNA makes the
3’UTR a likely target for post-transcriptional regulation.
We have been studying the effect of GAPDH protein onFigure 6 Ovarian cancer cell adhesiveness and motility is inhibited by
overexpression construct (miR-128OE), miR-152 overexpression construct (m
an 8 micron pore membrane for a 6 hour directed motility assay. B) Huma
miRNA overexpression construct transfected Hey cells 24 hours post transfeCSF-1 mRNA stability. GAPDH binds to the AREs in
CSF-1 mRNA 3’UTR and stabilizes CSF-1 mRNA.
Down-regulation of GAPDH by siRNA decreases CSF-1
expression in ovarian cancer cells [16].
In the present study, our goal was to identify miRNAs
that down-regulate CSF-1 expression, a small step in our
overall quest to find specific inhibitors which may ultim-
ately impact on ovarian cancer metastasis. By using in
silico text-mining algorithms against the CSF-1 mRNA
3’UTR, we selected miR-128 and miR-152 that would fit
the profile of having regulatory abilities of CSF-1. While
miR-128 and miR-152 possess target sequences in the
CSF-1 mRNA 3’UTR, their expression patterns in themiR-128 and miR-152. After transfection with, miR-128
iR-152OE), or Empty vector (pCMV-miR), Hey cells were plated on A)
n matrix-coated membrane for a 2 hour adhesion assay. C) Viability of
ction was determined by a cell proliferation assay.
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RNA level is lower in the invasive, metastatic Hey and
SKOV3 ovarian cancer cells in comparison to the less
invasive and tumorigenic Bix3 ovarian cancer cells
(Figure 1C). In contrast, miR-152 level was lower in the
Bix3 cells than in the Hey and SKOV3 ovarian cancer
cells (Figure 1D). Despite this difference in baseline ex-
pression pattern, we find that both miRNAs down-
regulated CSF-1 mRNA and protein in ovarian cancer
cells (Figure 5). A relatively small number of ovarian
cancer cell lines may not give sufficient information
when comparing miRNA expression patterns to effect
on target mRNA (CSF-1 mRNA).
The majority of the miRNAs originate from intergenic
regions far from other known genes and they possess in-
dependent transcription units. On the other hand, about
a quarter of human miRNA loci are intragenic and they
reside in the intronic regions of pre-mRNAs [42]. Most
of these latter ones will have a preferential sense orienta-
tion with the “host gene” and because they are lacking
their own promoters, as a result, will be processed from
introns [43]. Sharing a common promoter can result in
miRNAs and “host” genes exhibiting regulatory relation-
ships. In our study, both miR-128 and miR-152 reside in
introns of R3HDM1 gene and COPZ2 gene, respectively.
Their expression patterns follow those of their host tran-
scripts. COPZ2 encodes coatomer protein complex ζ2,
which is involved in intracellular traffic and autophagy
in golgi [40]. miR-152 and its host gene COPZ2 are
silenced in tumor cells and introduction of miR-152 pre-
cursor inhibited tumor cell (MDA-MB-231, HeLa)
growth [40]. Recently, both miR-128 and miR-152 have
been shown to inhibit neuroblastoma invasiveness [39].
These data suggest important biologic roles of miR-128
and miR-152 in cancer. In this report, we add the find-
ings that over-expression of miR-128 or miR-152 in
ovarian cancer cells results in a significant reduction in
both motility and adhesiveness (Figure 6), therefore inhi-
biting important aspects of invasiveness and metastasis.
There is a recent report stating that the predominant
effect of mammalian miRNAs is on mRNA decay which
results reduced translation [44]. In contrast, in zebra
fish, miR-430 reduced translation initiation prior to in-
ducing mRNA decay [45]. Djuranovic et al. [46] reported
miRNA-mediated translational repression is followed by
mRNA deadenylation. In addition, the concept of mRNA
destabilization by miRNAs gained support by genome-
wide observation studies [47]. In SKOV3, effects of ei-
ther miR-128 or miR-152 are more prominent on CSF-1
protein level than on the CSF-1 mRNA level (Figure 5A-
C). In contrast, in Bix3, both miRNAs have either a
similar or slightly more influence on the CSF-1 mRNA
level than CSF-1 protein level (Figure 5D-F). Different
cell lines, as expected, show some differential responsesto miRNAs, in part due to additional 3’UTR factors
which may regulate miRNA activity. Identifications of
these other regulatory factors are in progress in our
laboratory.
In CSF-1 mRNA 3’UTR, we identified three potential
miRNA target sequences for miR-128 and/or miR-152
(Figure 3). Target-A appears to be a miRNA ‘hot-spot’ as
our bioinformatics analysis predicted at least fourteen
miRNAs, including miR-128 and miR-152, targeting a re-
gion of 2573–2577 (Target-A) in CSF-1 mRNA 3’UTR
(Figure 3). This Target-A sequence is highly conserved
both in human and mouse [41]. Mutation of Target-A
resulted in a dramatic increase in reporter RNA and activ-
ity when compared to the wild-type construct (Figure 3).
Target-A mutation also abrogated response of reporter
RNA and activity to miR-128 and miR-152 over-expres-
sion (Figure 4). This suggests that Target-A is a critical
cis-acting regulatory sequence, and we have validated that
it serves as a direct target for at least miR-128 and miR-
152 (Figure 4).
Conclusion
The current study identifies miR-128 and miR-152 as
important regulators for CSF-1 mRNA and protein ex-
pression, and of ovarian cancer cell behavior. We iden-
tify an important CSF-1 3’UTR miRNA common target
sequence through which these miRNAs function.
Methods
Cell culture
Human ovarian cancer cells, Bix3, SKOV3 and Hey
[10,11], were grown in 10% fetal bovine serum-enriched
Dulbecco's Modified Eagle/F12 Ham’s medium (Invitro-
gen) supplemented with 1% penicillin-streptomycin
(HyClone). Immortalized ovarian epithelial cells NOSE.1
[32] were grown in M199/MCDB1051 supplemented with
15% FBS and 1% penicillin-streptomycin (HyClone). All
cells were incubated at 37°C and 5% CO2.
Quantitative real-time RT-PCR for miRNAs
Total RNA was extracted with Trizol (Invitrogen).
miRNA expression was determined by the stem-loop
qRT-PCR to increase the specificity of miRNA amplifica-
tion [48]. miRNA and tRNA specific cDNA synthesis
was followed by real-time PCR on an Eppendorf Real-
plex2 with tRNA as internal loading control. Reactions
were incubated during initial denaturation for 10 min at
95°C, then for 40 cycles of 15 sec at 95°C and 1 min
60°C. Final miRNA expression values were calculated
with the ΔΔCT method [49]. Primer sequences used are
shown in Table 2.
Similarly, CSF-1 and Luciferase transcripts were quan-
tified with real-time PCR using the following primer set
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GAPDH mRNA or G-418 RNA internal controls.
Splinted ligation
miRNA expression was confirmed by splinted ligation as
described by Maroney et al. [21]. In short, bridge and
ligation oligonucleotides were designed for the miRNAs
of interest. The ligation oligo was labeled with [γ-32P]-
ATP (Perkin Elmer, cat. no. BLU002A) using T4 poly-
nucleotide kinase (Fermentas). Separation of ligation
mixture was performed on a 10% urea gel and radioiso-
tope emission was detected by phosphor imager.
Transient transfection
Cells were plated on a 6 well plate one day prior to
transfection with 4 μg of plasmid DNA/well using 2.5:1
v/w ratio of Fugene HD (Promega). miRNA expression
vectors and miRNA target reporter vectors were pur-
chased from Origene.
Immunoblotting
Fifty μg of total protein lysates were subjected to SDS-
PAGE and electroblotted onto PVDF membrane. The
membranes were probed with mouse monoclonal anti-
CSF-1 (ab66236, Abcam) and anti-Pan Actin (ACTN05,
NeoMarkers, Fremont, CA) antibodies. After TBS-Twashes and incubation with anti-mouse (HRP)-conju-
gated secondary antibody, the proteins were detected
with a SuperSignal chemiluminescence (Pierce).
Mutation of CSF-1 mRNA 3’UTR targets
Each target was replaced by Asc I endonuclease site
which converts ‘TGCACTGA’ to ‘GGCGCGCC’ by PCR
cloning and fused to the 3’end of luciferase RNA in
pMir-Target (Origene).
Luciferase assay
Forty eight hours after transfection with the reporter
plasmid, cells were lysed and luciferase activity was
determined using the Dual Luciferase Assay System
according to the manufacturer’s protocol (Promega).
Transfection efficiency was determined (where needed)
by cotransfection with a GFP plasmid and microscopy.
Transwell motility assay and adhesion assay
For the directed motility assay, 24 hours post transfec-
tion, 4 x 104 cells were seeded in 1% Nu serum in the
top chamber of 24-well inserts with uncoated 8 μm pore
membranes (BD biosciences). The bottom chamber con-
tained 20% FBS and 12.5 μg/ml fibronectin as chemo-
attractants. Six hours after seeding, the top chamber
cells were wiped off with Q-tips and the top and bottom
chambers were washed with cold PBS, then dried and
frozen at -80°C for 30 minutes. Bottom chamber cells
were quantified by the lysis method using CyQuant Cell
Proliferation Assay Kit (Invitrogen) as per the manufac-
turer’s protocol.
For the adhesion assay, 24-well inserts with human
matrix-coated membranes (BD biosciences) were used.
The human matrix consisted of type IV collagen, laminin,
and gelatin. 24 hours post transfection, 5 x 104 Hey cells
were implanted and incubated for 2 hours prior to crystal
violet staining according to the previous report [11].
The WST-1 assay (Clontech) was used to assess degree
of cell proliferation among the conditions 24 after
transfection.
Statistical analysis
Data is depicted as mean ± SD from at least three inde-
pendent experiments. The one-way ANOVA test was
performed using SigmaStat (Jandel Scientific Corp.).
P < 0.05 was considered statistically significant. The Pear-
son product moment correlation test was performed
using SigmaStat (Jandel Scientific Corp.) for correlation
analysis between miRNA and CSF-1 mRNA or protein
expression levels.
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